November 11, 2021 7:35am

Question, is there a bounce after a trounce and how many?

Pre-open indications: 2 SELLs, 4 BUYs and 1 Pump (or No Promote)

Earnings: BioLife Solutions (BLFS)

What I provide is an intelligence daily. RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.

Remember that overnight and pre-open actions in futures doesn't necessarily translate into actual trading in the coming day’s session.

Remember those who have served, it’s Veteran’s Day – honor their service and memory!

Dow futures are UP +0.11% (+41 points), S&P futures are UP +0.34% (+16 points) and NASDAQ futures are UP +0.61% (+98 points)

 

U.S. stock futures were slightly up in early morning trading on Thursday, November 11, 2021

European stocks were flat,

Asia-Pacific stocks were mixed.

 

Henry’omics:

Indexes dived on Wednesday after a hot inflation report pushed up bond yields pressuring growth pockets of the market.

The stock market rally is in the midst of a pullback. The Dow and S&P 500 are at their 10-day lines, while the Nasdaq is still above its rising 21-day average. This retreat so far is normal and not surprising. <IBD>

 

If you didn’t remember what happen at Wednesday night’s close and the quarter’s “number’s” impact, you won’t be prepared for today’s session:

Wednesday’s evening’s recap: “RegMed Investors’ (RMi) closing bell: yet another pull-back that cut to the bone as the sector bleeds-out. Sentiment is enveloped by inflation.” …  https://www.regmedinvestors.com/articles/12178

Q4: November, 3 positive and 5 negative close to date

  • October, 8 positive and 13 negative closes

 

Companies in my headlights – It’s your decision; I provide an idea and context:

Maintaining SELL with a Pump or No Promote:

Biostage (BSTG) closed up +$0.18 with 2,006 shares traded after Tuesday’s -$0.03 with 3,304 shares traded, Monday’s +$0.07 with 7,082 shares traded after being down -$0.60, Friday’s flat again at $2.60 with 9,003 shares traded and last Thursday’s flat with 82 shares traded, the previous Wednesday’s -$0.40 to $2.60 with 1,208 shares traded, Tuesday’s -$0.10 to $3.00 with 200 shares traded following Monday’s flat again with 80 shares traded.

  • What’s there to invest in – the “Sword of Damocles” hanging over its recent insurance company rejection of legal expense/costs of a terminal death suit against the company?
  • For a company with NO clinical trial, an a one (1) and a half year approved IND, four (4) employees and NO CRO <clinical research organization> initiation.

 

Probabilities versus aftermarket/pre-open share pricing indication moves:

Maintaining SELL into Strength:

Chinook Therapeutics (KDNY) closed up +$1.47 to $15.98 after Tuesday’s +$0.32 to $14.51 and Monday’s -$1.77 with a pre-market indication of -$0.38 or -2.38% after executing an up-sized offering.

 

Maintaining SELL:

BioLife Solutions (BLFS) closed down -$3.90 to $49.61 after Tuesday’s +$0.28 to $53.51, Monday’s -$0.59, Friday’s -$4.73 and last Thursday’s +$0.14 and the previous Wednesday’s +$3.29 and Tuesday’s +$1.06) with NO aftermarket indication. Today is earnings release.

 

Maintaining BUY after trounce:

AxoGen (AXGN) closed down -$0.47 to $12.93 after Tuesday’s $13.40 and Monday’s $14.32 with a positive +$0.21 or +1.62% pre-market indication.

Editas Medicine (EDIT) closed down again -$2.67 to $37.89 after Tuesday’s -$0.01 to $40.56, Monday’s +$3.07 to $40.57, Friday’s -$0.34 and last Thursday’s -$0.85 with a positive pre-market of +$0.16 or +0.42%.

Intellia Therapeutics (NTLA) closed down -$11.58 to $126.78 after Tuesday’s +$2.29 to $138.36, Monday’s +$0.59 to $136.07, Friday’s+$1.54 and last Thursday’s -$1.97 with a positive +$1.27 or +1% pre-open indication.

Global Blood Therapeutics (GBT) closed down -$0.87 to $32.59, Tuesday’s $33.46 and Monday’s $35.40 with a positive +$1.41 or +4.33% pre-market indication.

 

 

The BOTTOM LINE: Most of these sector stocks have had been lately losers.

But many haven’t been losers overnight, not a great sign for this market. LPS (loss-per-share) earnings and revenues were all over the map, but they still have good runway’s i.e., cash positions for minimum two (2) years.

As I mentioned, in the title, “is there a bounce after a trounce and how many?”

I am still manning the bully pulpit, expressing the theme of “Reducing exposure as well as being patient in your willingness to stay fully invested, I’d been recommending very careful buy-ins for the hopes of gains through the month and year-end.

We are seeing to date, one (1) net income – Bellicum Pharmaceuticals (BLCM),

  • Twenty-one (21) net losses to date <uniQure (QURE), Alnylam Pharmaceuticals (ALNY), Regenxbio (RGNX), Sage Therapeutics SAGE), Ultragenyx Pharmaceuticals (RARE), Voyager Therapeutics (VYGR), Solid Biosciences (SLDB), Ionis Pharmaceuticals (IONS), CRISPR Therapeutics (CRSP), Intellia Therapeutics (NTLA), Caladrius Biosciences (CLBS), AxoGen (AXGN), Adverum Biotechnologies (ADVM), Verastem (VSTM), Global Blood Therapeutics (GBT), Fate Therapeutics (FATE), Sangamo Therapeutics (SGMO),  Cellectis SA (CLLS), Editas Medicine (EDIT) and today’s … Applied Genetic Technologies (AGTC) and Vericel (VCEL)>

… Earning’s releases that initiated Q3 earnings reporting season and beginning the tug-of-war between share pricing that is softer than usual and the usual LPS (loss-per-share) to be less than estimates and expectations.

The stem, cell and gene therapy earnings continue with BioLife Solutions (BLFS) today followed by Athersys (ATHX) and Brainstorm Cell Therapeutics (BCLI) coming 11/15 (to date).

I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim any new highs if one can!”

RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.

WHY do I keep analyzing Biostage (BSTG): When one sees an inextricable wrong and morally repulsive scenario; it takes courage, resolve and patience to stay the course of asking the questions without response!

 

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.